Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) announced contributions from Chief Clinical Officer Reid Robison, who published four peer-reviewed papers in 2023 about innovative mental health treatments. These studies focus on conditions such as PTSD, depression, and anxiety, showcasing advancements in psychedelic-assisted therapies. Key highlights include the effectiveness of ketamine-assisted psychotherapy for healthcare workers with PTSD, the positive impact of cannabis-assisted psychotherapy, and promising breathwork interventions for anxiety. Numinus aims to integrate evidence-based treatments into mainstream clinical practice, propelling the mental health sector forward.
- Chief Clinical Officer Reid Robison published four peer-reviewed papers in 2023, validating Numinus's research efforts.
- Studies demonstrated effective treatment options, including ketamine and cannabis-assisted therapies for PTSD and depression.
- Numinus is advancing the integration of innovative treatments into mainstream healthcare.
- None.
VANCOUVER, BC, March 21, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Reid Robison, Chief Clinical Officer of Numinus, has contributed to studies published in four peer-reviewed papers thus far in 2023 for his work in the treatment of mental health disorders including Post-Traumatic Stress Disorder (PTSD), depression, and anxiety.
"Dr. Reid Robison continues to make key contributions to the study of new and innovative treatments for mental health disorders, such as PTSD, depression, and anxiety. With his work published in peer-reviewed journals such as the Journal of Psychoactive Drugs, Frontiers in Psychiatry, Brain Sciences and Journal of Psychedelic Studies, our industry is gaining further validation as new treatments are on track to becoming viable healing options for the large patient population in need," said Payton Nyquvest, Founder and CEO. "At Numinus we are focused on providing a holistic, integrated approach to healing, with all provided treatments being evidence-based. We closely monitor advancing research to ensure Numinus is prepared to treat place patients look to when treatments become available."
Title: Ketamine-Assisted Group Psychotherapy for Frontline Healthcare Workers with COVID-19-Related Burnout and PTSD: A Case Series of Effectiveness/Safety for 10 Participants
Publication: Journal of Psychoactive Drugs.
Date: March 2, 2023
Key Takeaways:
- Weekly group ketamine-assisted psychotherapy and integration provided immediate improvements in treating 10 frontline healthcare workers experiencing burnout, PTSD, depression, and anxiety.
- Ketamine was well tolerated, and no significant adverse events were reported.
Title: Cannabis-assisted psychotherapy for complex dissociative posttraumatic stress disorder: A case report
Publication: Frontiers in Psychiatry
Date: February 9, 2023
Key Takeaways:
- Cannabis-assisted psychotherapy, where sessions were primed with psychoeducation and intention setting, displayed effects comparable to those produced by classic and non-classic psychedelics, such as psilocybin and ketamine.
Title: Breathwork Interventions for Adults with Clinically Diagnosed Anxiety Disorders: A Scoping Review
Publication: Brain Sciences
Date: February 2, 2023
Key Takeaways:
- This study supported that breathwork interventions may be an effective treatment option for patients suffering anxiety.
- Proposed next steps are to research are the optimization and standardization of breathwork practices and protocols for the treatment of anxiety disorders.
Title: Registered clinical trials investigating ketamine and esketamine for treatment-resistant depression: A systematic review
Publication: Journal of Psychedelic Studies
Date: January 16, 2023
Key Takeaways:
- Although there are many clinical trials taking place on the study of esketamine over ketamine for Treatment Resistant Depression, this review suggests more patient characteristics need to be considered that may affect treatment response, such as age, sex, and race.
Numinus Wellness (TSX: NUMI) (OTCQX: NUMIF) helps people to heal and be well through the development and delivery of innovative mental healthcare and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model - including psychedelic production, research and clinic care - is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.
Learn more at www.numinus.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.
Statements and other information contained in this press release about anticipated future events constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect" and "intend" and statements that an event "may", "will", "should", "could" or "might" occur or other similar expressions. Forward-looking statements are subject to risks and uncertainties and other factors that could cause actual results to differ materially from those contained in the forward-looking statements, including the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early-stage clinical trials may not be predictive of results in later-stage or large-scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected results from additional data or analysis obtained during clinical trials or the occurrence of adverse safety events; availability of funding for subsequent clinical trials; results of subsequent clinical trials; uncertainty of developing, launching, or commercializing any product or service based on clinical research; failure to obtain, protect, and enforce our data, intellectual property, and other proprietary rights and the risks and uncertainties relating to intellectual property claims and challenges; risks associated with current and potential future healthcare reforms; and any other risks and uncertainties that are described in other reports we have filed under Numinus' profile on www.sedar.com. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. The Company does not undertake any obligation to update forward-looking statements even if circumstances or management's estimates or opinions should change except as required by applicable laws. Investors should not place undue reliance on forward-looking statements.
View original content:https://www.prnewswire.com/news-releases/numinus-announces-four-peer-reviewed-publications-from-its-chief-clinical-officer-in-2023-301777134.html
SOURCE Numinus Wellness Inc.
FAQ
What recent studies has Numinus Wellness published in 2023 involving mental health treatments?
Who is the Chief Clinical Officer of Numinus Wellness responsible for the recent publications?
What are the key findings from Numinus's studies published in 2023?
How is Numinus Wellness contributing to mental health care innovation?
What is the stock symbol for Numinus Wellness?
